← All trials
NCT04661930
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2020
- Primary completion
- Apr 1, 2021
- Completion date
- Dec 1, 2021
- First posted
- Dec 10, 2020
- Last posted
- Dec 10, 2020
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hebrew UniversityLead sponsor
- Barzilai Medical CenterCollaborator
- Barzilai Medical CenterStudy director
- Barzilai Medical CenterOverall official - principal investigator
- Hebrew UniversityOverall official - principal investigator
- Hebrew UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.